Evidence map›Paper›PMID 42242868›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2026

Translational Theranostics in Glioblastoma: FAPI-46 as a Precision Medicine Tool.

Pauline Jeanjean, Abir Swaidan, Christopher Tse, Samantha Kwock, Iveta Fajnorova, Rachel Dove, Ines Camille Azrour, Sarah Taylor, Begonya Comin-Anduix, David A Nathanson and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Pauline JeanjeanAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Abir SwaidanAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Christopher TseAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Samantha KwockAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Iveta FajnorovaAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Rachel DoveAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Ines Camille AzrourAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Sarah TaylorAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Begonya Comin-AnduixAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
David A NathansonAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Giuseppe CarlucciAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Jérémie CalaisAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Johannes CzerninAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Élie Besserer-OffroyAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; cmona@mednet.ucla.edu elie@bessererlab.org.
Christine E MonaAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; cmona@mednet.ucla.edu elie@bessererlab.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma represents the most lethal form of brain cancer, characterized by a 5-y survival rate of approximately 4%. Fibroblast activation protein (FAP), expressed within both the tumor microenvironment and glioblastoma cells, has been identified as a promising therapeutic target. This study explores the potential of FAP-targeted molecular probes as theranostic agents for glioblastoma.

Indexed as

Brain NeoplasmsGelatinasesGlioblastomaMembrane ProteinsPrecision MedicineTheranostic NanomedicineAnimalsCell Line, TumorEndopeptidasesFemaleFibroblast Activation Protein AlphaGallium RadioisotopesHumansMaleMiceSerine EndopeptidasesEndopeptidasesFibroblast Activation Protein AlphaGallium RadioisotopesGelatinasesMembrane ProteinsSerine Endopeptidasesfibroblast activation proteinglioblastomaimmunomodulationtargeted radiopharmaceutical therapytheranostics

Identifiers

PMID42242868
PMCPMC13544249

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.